Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes and endpoints of postoperative recurrence in Crohn's Disease: systematic review and consensus conference.
Hammoudi N, Sachar D, D'Haens G, Reinisch W, Kotze PG, Vermeire S, Schölmerich J, Kamm MA, Griffiths A, Panes J, Ghosh S, Siegel CA, Bemelman W, O'Morain C, Steinwurz F, Fleshner P, Mantzaris GJ, Sands B, Abreu MT, Dotan I, Turner D, Dignass A, Allez M; International Organization for the Study of Inflammatory Bowel Diseases (IOIBD).. Hammoudi N, et al. Among authors: sands b. J Crohns Colitis. 2023 Dec 19:jjad205. doi: 10.1093/ecco-jcc/jjad205. Online ahead of print. J Crohns Colitis. 2023. PMID: 38112601
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Peyrin-Biroulet L, Dubinsky MC, Sands BE, Panés J, Schreiber S, Reinisch W, Feagan BG, Danese S, Yarur AJ, D'Haens GR, Goetsch M, Wosik K, Keating M, Lazin K, Wu J, Modesto I, McDonnell A, Bartolome L, Vermeire S. Peyrin-Biroulet L, et al. Among authors: sands be. J Crohns Colitis. 2024 Apr 13:jjae038. doi: 10.1093/ecco-jcc/jjae038. Online ahead of print. J Crohns Colitis. 2024. PMID: 38613425
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
Sands BE, D'Haens G, Panaccione R, Regueiro M, Ghosh S, Hudesman D, Ahmad HA, Mehra D, Wu H, Jain A, Petersen A, Osterman MT, Afzali A, Danese S. Sands BE, et al. Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00405-1. doi: 10.1016/j.cgh.2024.03.042. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38723981 Free article.
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
Panés J, D'Haens GR, Sands BE, Ng SC, Lawendy N, Kulisek N, Guo X, Wu J, Vranic I, Panaccione R, Vermeire S. Panés J, et al. Among authors: sands be. United European Gastroenterol J. 2024 May 22. doi: 10.1002/ueg2.12584. Online ahead of print. United European Gastroenterol J. 2024. PMID: 38778549 Free article.
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
D'Haens G, Higgins PDR, Peyrin-Biroulet L, Sands BE, Lee S, Moses RE, Redondo I, Escobar R, Gibble TH, Keohane A, Morris N, Zhang X, Arora V, Kobayashi T. D'Haens G, et al. Inflamm Bowel Dis. 2024 Jan 25:izae004. doi: 10.1093/ibd/izae004. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38271613
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Feagan BG, et al. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734. N Engl J Med. 2013. PMID: 23964932 Free article. Clinical Trial.
408 results